Literature DB >> 24475421

Treatment of renal manifestations of ANCA-associated vasculitis.

Kresimir Galesic1, Danica Ljubanovic2, Ivica Horvatic1.   

Abstract

CONTEXT: Vasculitis is a clinicopathological entity characterized by inflammation and necrosis of blood vessels. EVIDENCE ACQUISITIONS: Directory of Open Access Journals (DOAJ), Google Scholar, Pubmed (NLM), LISTA (EBSCO) and Web of Science have been searched.
RESULTS: Two major autoantigens for ANCA are myeloperoxidase (MPO) and proteinase 3 (PR3), which are proteins in the primary granules of neutrophils and in the lysosomes of monocytes. They are expressed in mature neutrophils of patients with ANCA, while absent in healthy subjects.
CONCLUSIONS: The kidney is the most commonly affected vital organ in ANCA-associated vasculitis, and patient outcomes are largely determined by the severity of renal disease at diagnosis and by its response to treatment.

Entities:  

Keywords:  ANCA-associated small-vessel vasculitis; Antineutrophil cytoplasmatic autoantibody; Chapel Hill Consensus Conference classification; Crescentic glomerulonephritis; Vasculitis

Year:  2013        PMID: 24475421      PMCID: PMC3886180          DOI: 10.5812/nephropathol.8971

Source DB:  PubMed          Journal:  J Nephropathol        ISSN: 2251-8363


  40 in total

1.  Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups.

Authors:  Herbert A Hauer; Ingeborg M Bajema; Hans C van Houwelingen; Franco Ferrario; Laure-Hélène Noël; Rüdiger Waldherr; David R W Jayne; Niels Rasmussen; Jan A Bruijn; E Christiaan Hagen
Journal:  Kidney Int       Date:  2002-01       Impact factor: 10.612

2.  Pulmonary-renal syndrome, diffuse pulmonary hemorrhage and glomerulonephritis, associated with Wegener's granulomatosis effectively treated with early plasma exchange therapy.

Authors:  Toshiro Sugimoto; Naoko Deji; Shinji Kume; Norihisa Osawa; Masayoshi Sakaguchi; Keiji Isshiki; Daisuke Koya; Atsunori Kashiwagi
Journal:  Intern Med       Date:  2007-01-01       Impact factor: 1.271

3.  Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides.

Authors:  A R Exley; P A Bacon; R A Luqmani; G D Kitas; C Gordon; C O Savage; D Adu
Journal:  Arthritis Rheum       Date:  1997-02

Review 4.  The clinical spectrum of primary renal vasculitis.

Authors:  Michael Samarkos; Sozos Loizou; George Vaiopoulos; Kevin A Davies
Journal:  Semin Arthritis Rheum       Date:  2005-10       Impact factor: 5.532

5.  A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis.

Authors:  L Guillevin; J F Cordier; F Lhote; P Cohen; B Jarrousse; I Royer; P Lesavre; C Jacquot; P Bindi; P Bielefeld; J F Desson; F Détrée; A Dubois; E Hachulla; B Hoen; D Jacomy; C Seigneuric; D Lauque; M Stern; M Longy-Boursier
Journal:  Arthritis Rheum       Date:  1997-12

6.  Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Eugene P Rhee; Karen A Laliberte; John L Niles
Journal:  Clin J Am Soc Nephrol       Date:  2010-05-24       Impact factor: 8.237

7.  A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.

Authors:  David Jayne; Niels Rasmussen; Konrad Andrassy; Paul Bacon; Jan Willem Cohen Tervaert; Jolanta Dadoniené; Agneta Ekstrand; Gill Gaskin; Gina Gregorini; Kirsten de Groot; Wolfgang Gross; E Christiaan Hagen; Eduardo Mirapeix; Erna Pettersson; Carl Siegert; Alberto Sinico; Vladimir Tesar; Kerstin Westman; Charles Pusey
Journal:  N Engl J Med       Date:  2003-07-03       Impact factor: 91.245

8.  Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.

Authors:  Christian Pagnoux; Alfred Mahr; Mohamed A Hamidou; Jean-Jacques Boffa; Marc Ruivard; Jean-Pierre Ducroix; Xavier Kyndt; François Lifermann; Thomas Papo; Marc Lambert; José Le Noach; Mehdi Khellaf; Dominique Merrien; Xavier Puéchal; Stéphane Vinzio; Pascal Cohen; Luc Mouthon; Jean-François Cordier; Loïc Guillevin
Journal:  N Engl J Med       Date:  2008-12-25       Impact factor: 91.245

9.  Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.

Authors:  R A Luqmani; P A Bacon; R J Moots; B A Janssen; A Pall; P Emery; C Savage; D Adu
Journal:  QJM       Date:  1994-11

10.  Predictors of outcome in idiopathic rapidly progressive glomerulonephritis (IRPGN).

Authors:  Efstathios Alexopoulos; Lazaros Gionanlis; Ekaterini Papayianni; Elizabeth Kokolina; Maria Leontsini; Dimitrios Memmos
Journal:  BMC Nephrol       Date:  2006-11-01       Impact factor: 2.388

View more
  3 in total

1.  Association of proteinuria with various clinical findings and morphologic variables of oxford classification in immunoglobulin a nephropathy patients.

Authors:  Hamid Nasri; Yahya Madihi; Alireza Merrikhi; Allaleh Gheissari; Azar Baradaran; Soleiman Kheiri; Mahmoud Rafieian-Kopaei
Journal:  Int J Prev Med       Date:  2013-05

2.  ANCA positivity in a patient with infective endocarditis-associated glomerulonephritis: a diagnostic dilemma.

Authors:  Gopal Chandra Ghosh; Brijesh Sharma; Bhimarey Katageri; Minakshi Bhardwaj
Journal:  Yale J Biol Med       Date:  2014-09-03

3.  Induction monotherapy with sirolimus has selected beneficial effects on glomerular and tubulointersititial injury in nephrotoxic serum nephritis.

Authors:  Lena Succar; Julia Lai-Kwon; David J Nikolic-Paterson; Gopala K Rangan
Journal:  Int J Nephrol Renovasc Dis       Date:  2014-07-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.